Search results
Novartis to showcase next-gen manufacturing solutions at BIO 2024
BioPharma-Reporter· 21 hours agoAt BIO 2024, Novartis Contract Manufacturing will actively demonstrate its commitment to supporting...
2024's worst cities for grass allergies this summer
Stacker via AOL· 15 hours agoFor each of the 378 biggest U.S. cities, we then gathered data on each factor from the American Academy of Allergy, Asthma & Immunology, Lawn Love,...
Earnings call: Nektar Therapeutics optimistic on REZPEG and pipeline progress By Investing.com
Investing.com· 6 days agoNektar Therapeutics (NASDAQ:NKTR) reported a productive first quarter of 2024, focusing on their ...
In RA Treatment, Don't Overlook Underlying CV Risks
Medscape· 5 hours agoPatients with rheumatoid arthritis (RA) carry a high risk for cardiovascular events, but mounting clinical evidence suggests they're being undertreated...
Study highlights next-gen probiotic’s potential to protect against respiratory infection
Nutraingredients.com· 2 days agoWriting in Frontiers in Immunology, scientists from the French National Institute of Health and...
Faculty Recruitment, Westlake University School of Medicine - Hangzhou, Zhejiang, China job with...
Nature· 1 hour agoFounded in 2018, Westlake University is a new type of non-profit research-oriented university in Hangzhou, China, supported by public and private funding. Preceded by the Westlake Institute ...
Biohaven Ltd. (NYSE:BHVN) Given Average Rating of “Buy” by Analysts
ETF DAILY NEWS· 8 hours agoBiohaven Ltd. (NYSE:BHVN – Get Free Report) has been given an average rating of “Buy” by the eight brokerages that are currently covering the company, MarketBeat Ratings reports. Several equities ...
How a Brooklyn hospital is working to represent the community's growing Asian population
CBS News· 12 hours agoOne Brooklyn hospital is making an effort to represent the growing Asian community it serves....
Nektar Therapeutics (NKTR) First Quarter 2024 Earnings Overview
Guru Focus· 6 days agoThe biopharmaceutical company, known for its innovative approach in immunology and oncology, reported a net loss of $36.8 million, or $0.19 per share, aligning with analyst ...
2024's worst cities for grass allergies this summer - KVIA
ABC 7 El Paso· 1 hour agoLawn Love ranked nearly 380 U.S. cities to help determine 2024's worst cities for grass allergies...